Preliminary Report of the Use of Everolimus in a Patient with Progressive Medullary Thyroid Carcinoma

Preliminary Report of the Use of Everolimus in a Patient with Progressive Medullary Thyroid Carcinoma

Show other versions (2)

Bibliographic Details
Main Authors:	Druce, M, Maher, K, Grozinsky-Glasberg, S, Gross, D, Chambers, J, Grossman, A
Format:	Conference item
Published:	2010

Similar Items

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
by: Druce, M, et al.
Published: (2012)

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma.
by: Druce, M, et al.
Published: (2012)

The Rapamycin Derivative RAD001 (Everolimus) Inhibits Cell Proliferation and Interacts with the Akt-mTOR-p70S6K Pathway in Human Medullary Thyroid Carcinoma Cells
by: Grozinsky-Glasberg, S, et al.
Published: (2009)

The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
by: Grozinsky-Glasberg, S, et al.
Published: (2010)

In-situ analysis of calcitonin and CGRP expression in medullary thyroid carcinoma.
by: Boultwood, J, et al.
Published: (1990)

Medullary thyroid carcinoma and duodenal calcitonin-secreting neuroendocrine tumour: more than coincidence?
by: Huguet, I, et al.
Published: (2013)

Everolimus therapy for progressive adrenocortical cancer
by: Fraenkel, M, et al.
Published: (2013)

Everolimus therapy for progressive adrenocortical cancer.
by: Fraenkel, M, et al.
Published: (2013)

Medullary thyroid cancer: molecular biology and novel molecular therapies.
by: Cakir, M, et al.
Published: (2009)

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
by: Chan, H, et al.
Published: (2010)

Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
by: Van Allen, Eliezer M., et al.
Published: (2017)

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
by: Druce, MR, et al.
Published: (2009)

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
by: Mukherjee, J, et al.
Published: (2001)

Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum
by: Zhou, Jingan, et al.
Published: (2021)

Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum
by: Zhou, Jingan, et al.
Published: (2022)

The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
by: Grozinsky-Glasberg, S, et al.
Published: (2011)

EVEROLIMUS PLUS OCTREOTIDE LAR IN PATIENTS WITH LUNG CARCINOIDS
by: Granberg, D, et al.
Published: (2014)

Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time Reply
by: Jr, W, et al.
Published: (2012)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
by: Gupta, P, et al.
Published: (2014)

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
by: Wells, SA, et al.
Published: (2012)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
by: Sen Gupta, P, et al.
Published: (2014)

Evaluation of the Association between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
by: Den Gupta, P, et al.
Published: (2011)

Metastatic follicular thyroid carcinoma to the mandible: a case report
by: Zain, R.B., et al.
Published: (2009)

Medullary carcinoma of the breast : role of contrastenhanced MRI in the diagnosis of multiple breast lesions.
by: Abdul Rashid, Saiful Nizam, et al.
Published: (2009)

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

IGF2-induced hypoglycemia unresponsive to everolimus.
by: Korevaar, T, et al.
Published: (2014)

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer
by: McFadden, David Glenn, et al.
Published: (2014)

Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study.
by: Rinaldi, S, et al.
Published: (2014)

Adrenocortical Cancer: A Therapeutic Approach with Everolimus (RAD001)
by: Gueorguiev, M, et al.
Published: (2010)

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Combination of everolimus with sorafenib for solid renal tumors in Tsc2+/- mice is duperior to everolimus alone
by: Yang, J, et al.
Published: (2017)

Phase-3 randomized trial of everolimus (RAD001) vs. placebo in advanced pancreatic NET (RADIANT-3)
by: Chambers, J, et al.
Published: (2010)

Everolimus for renal angiomyolipoma in tuberous sclerosis.
by: Sooriakumaran, P, et al.
Published: (2013)

Dandy-Walker malformation, papillary thyroid carcinoma, and SDHD-associated paraganglioma syndrome.
by: Huguet, I, et al.
Published: (2013)

Metastatic thyroid carcinoma presenting with spinal cord compression.
by: Hassan, H. A., et al.
Published: (2010)

Cancer in the thyroid is not always thyroid cancer.
by: Akester, K, et al.
Published: (2003)

An unusual first presentation of hypopharyngeal carcinoma as thyroid abscess: Case report of a diagnostic challenge
by: Heng Yao Tan, et al.
Published: (2021)

Effect of Everolimus plus Octreotide LAR in Patients With Advanced Lung Neuroendocrine Tumours - Analysis From RADIANT-2
by: Fazio, N, et al.
Published: (2011)

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

MicroRNA profiling of papillary thyroid carcinoma cell lines
by: Smyth, P, et al.
Published: (2007)